Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating subcutaneous amlitelimab for moderate-to-severe atopic dermatitis in patients 12 and older with inadequate response to prior b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 3 | Status: RECRUITING